April 19, 2005 — Implantation of a minimally invasive diaphragm pacing system (DPS) with therapeutic electrostimulation may help maintain diaphragm function and slow or arrest the rate of respiratory ...
Please provide your email address to receive an email when new articles are posted on . Synapse Biomedical has received premarket approval from the FDA for its NeuRx Diaphragm Pacing System, which ...
Oberlin-based Synapse Biomedical recently secured U.S. Food and Drug Administration premarket approval for its diaphragm pacing system for use in patients with spinal cord injuries (SCI) who rely on ...
Synapse Biomedical Inc. has won breakthrough device designation from the FDA for its Transaeris system, a diaphragm pacing system (DPS) for use in weaning patients off mechanical ventilation. The ...
Synapse Biomedical Inc. has won breakthrough device designation from the FDA for its Transaeris system, a diaphragm pacing system (DPS) for use in weaning patients off mechanical ventilation. The ...
OBERLIN, Ohio, April 5, 2023 /PRNewswire/ -- Synapse Biomedical, Inc. announced today that the FDA has granted premarket approval (PMA) of the NeuRx ® Diaphragm Pacing System (NeuRx DPS ®) for use in ...
October 14, 2010 — The US Food and Drug Administration (FDA) has granted humanitarian use device designation for a diaphragm pacing system (NeuRx; Synapse Biomedical, Inc) in patients with amyotrophic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results